Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Novartis AG Receives European Approval For Meningitis B Vaccine-Reuters
Reuters reported that Novartis AG has clinched European approval for the first vaccine against meningitis B, and will seek to sell the drug as soon as possible.
Latest Developments for Novartis AG
- Novartis AG's Drug Ilaris Approved By FDA To Treat Active Systemic Juvenile Idiopathic Arthritis
- Pfizer Inc, Novartis AG And Abbott Laboratories Weigh Bids For Brazil's Ache Laboratorios Farmaceuticos-Reuters
- UK Cost Body Rejects Novartis AG's Breast Cancer Drug-Reuters
- UK Cost Agency Says No To Novartis AG's Blood Cancer Drug Jakavi-Reuters
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters